Skip to main content
. 2022 Mar 23;5(3):e223827. doi: 10.1001/jamanetworkopen.2022.3827

Table 3. Diagnostic Outcomes of Unmatched and Propensity Score–Matched Groups.

Outcome No. (%)
Unmatched participants Propensity score–matched (1:1) participants
Total (n = 67 683), No. (%) Received cimetropium bromide (n = 28 280), No. (%) Did not receive cimetropium bromide (n = 39 403), No. (%) P valuea Total (n = 41 670), No. (%) Received cimetropium bromide (n = 20 835), No. (%) Did not receive cimetropium bromide (n = 20 835), No. (%) P valuea
Total gastric neoplasms 160 (0.24) 87 (0.31) 73 (0.19) .001 102 (0.24) 63 (0.30) 39 (0.19) .02
Dysplasia 85 (0.13) 44 (0.16) 41 (0.10) .06 52 (0.12) 32 (0.15) 20 (0.10) .10
Early cancer 61 (0.09) 36 (0.13) 25 (0.06) .006 40 (0.10) 25 (0.12) 15 (0.07) .11
Advanced cancer 10 (0.01) 6 (0.02) 4 (0.01) .34 7 (0.02) 5 (0.02) 2 (0.01) .26
Lymphoma 3 (0.004) 1 (0.004) 2 (0.01) >.99 3 (0.01) 1 (0.005) 2 (0.01) .56
Neuroendocrine tumor 1 (0.001) 0 1 (0.003) >.99 0 0 0 NA
Dysplasia and early cancer 146 (0.22) 80 (0.28) 66 (0.17) .002 92 (0.22) 57 (0.27) 35 (0.17) .02
Small gastric neoplasmsb 56 (0.08) 35 (0.12) 21 (0.05) .002 35 (0.08) 24 (0.12) 11 (0.05) .03
Dysplasia 42 (0.06) 26 (0.09) 16 (0.04) .008 26 (0.06) 18 (0.09) 8 (0.04) .05
Early cancer 14 (0.02) 9 (0.03) 5 (0.01) .09 9 (0.02) 6 (0.03) 3 (0.01) .32
Location
Cardia and fundus 5 (0.01) 2 (0.01) 3 (0.01) >.99 4 (0.01) 2 (0.01) 2 (0.01) >.99
Body 72 (0.11) 44 (0.16) 28 (0.07) .001 49 (0.12) 34 (0.16) 15 (0.07) .007
Antrum 82 (0.12) 40 (0.14) 42 (0.11) .20 49 (0.12) 27 (0.13) 22 (0.11) .48

Abbreviation: NA, not available.

a

P values were determined using an χ2 test or a Fisher exact test for unmatched data and a McNemar test for matched data.

b

Neoplasms <1 cm in diameter.